ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual ...

Novocure Ltd (NASDAQ:NVCR) announced that its Premarket Approval (PMA) application seeking approval for the use of Tumor Treating Fields (TTFields) therapy together with standard systemic therapies ...

CHICAGO -- Treatment with tumor treating field (TTFields) therapy combined with standard of care improved overall survival versus standard of care alone in patients with metastatic non-small cell lung ...

Novocure Limited NVCR announced meeting the primary endpoint of overall survival (OS) in a late-stage study, which evaluated the use of Tumor Treating Fields (TTFields) therapy concomitantly with ...

The MarketWatch News Department was not involved in the creation of this content. METIS trial achieved its primary endpoint, showing a statistically significant delay in time to intracranial ...

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed additional data on Saturday from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer.

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved significantly versus chemotherapy with the addition of tumor treating fields ...

On Monday, NovoCure Ltd (NASDAQ:NVCR) and Zai Lab Limited (NASDAQ:ZLAB) revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine ...

Zai Lab Limited (NASDAQ:ZLAB) and NovoCure Limited (NASDAQ:NVCR) revealed landmark results from the Phase 3 PANOVA-3 trial at the 2025 ASCO Annual Meeting, marking the first therapy to show ...